AOD-9604 and Tesamorelin are two synthetic peptides associated with growth hormone biology and metabolic research. Although both compounds are frequently discussed in relation to lipid metabolism, their molecular structures, biological mechanisms, and clinical research findings are significantly different.
AOD-9604 is a modified fragment of human growth hormone (HGH). Researchers originally developed it to investigate specific metabolic activities associated with the C-terminal region of the hormone.
Tesamorelin, on the other hand, is a synthetic analog of growth hormone-releasing hormone (GHRH). It activates receptors in the pituitary gland, stimulating the release of endogenous growth hormone.
These differences are important because the two peptides do not have the same molecular targets or established biological activities.
This AOD-9604 vs Tesamorelin comparison explores their amino acid structures, mechanisms of action, metabolic research, scientific evidence, and laboratory characteristics.
What Is the Difference Between AOD-9604 and Tesamorelin?
The main difference between AOD-9604 and Tesamorelin is their relationship with the growth hormone system.
AOD-9604 is derived from human growth hormone itself, while Tesamorelin is derived from the hormone that stimulates growth hormone secretion.
In simpler terms:
- AOD-9604: A modified growth hormone fragment investigated for selected metabolic activities.
- Tesamorelin: A GHRH analog that stimulates growth hormone release through an established endocrine signaling pathway.
Although both compounds are peptides, their molecular structures and mechanisms should not be considered interchangeable.
AOD-9604 vs Tesamorelin: Quick Comparison
| Feature | AOD-9604 | Tesamorelin |
|---|---|---|
| Peptide classification | HGH fragment analog | GHRH analog |
| Amino acids | 16 | 44 |
| Parent molecule | Human growth hormone | Growth hormone-releasing hormone |
| Molecular weight | Approximately 1,815.1 Da | Approximately 5,135.9 Da |
| Structural modification | Added N-terminal tyrosine | N-terminal trans-3-hexenoyl modification |
| Disulfide bond | Present | No corresponding internal bridge |
| Primary receptor | Not definitively established | GHRH receptor |
| Growth hormone release | Not established as a GH secretagogue | Stimulates GH secretion |
| IGF-1 activity | No established HGH-like systemic effect | Increases IGF-1 through GH signaling |
| Primary research interest | Lipid metabolism and peptide fragments | Endocrine signaling and visceral adipose tissue |
| FDA status | Not approved | Approved in specific prescription formulations |
These distinctions form the foundation of the scientific comparison.
What Is AOD-9604 Peptide?
AOD-9604, also known as Anti-Obesity Drug 9604, is a synthetic peptide derived from the C-terminal region of human growth hormone.
The compound contains 16 amino acids and represents a modified version of the HGH 177–191 fragment.
Human growth hormone is a protein consisting of 191 amino acids. Because the complete protein participates in multiple biological processes, researchers became interested in examining whether smaller molecular regions could exhibit selected activities independently.
AOD-9604 was developed through this approach.
Early experiments investigated the peptide’s possible interactions with lipid metabolism, adipose tissue, and metabolic signaling.
However, the compound’s proposed biological activities have not translated into established clinical effectiveness for weight reduction.
AOD-9604 remains an investigational compound and is not approved by the FDA for therapeutic use.
Researchers seeking additional chemical information can consult Orion Peptides’ AOD-9604 technical reference, which covers its amino acid sequence, molecular properties, and structural characteristics.
What Is Tesamorelin Peptide?
Tesamorelin is a synthetic analog of growth hormone-releasing hormone.
GHRH is naturally produced in the hypothalamus and helps regulate growth hormone secretion from the pituitary gland.
Tesamorelin contains 44 amino acid residues and incorporates a chemical modification at the N-terminus.
This modification distinguishes the synthetic peptide from naturally occurring GHRH.
Tesamorelin interacts with growth hormone-releasing hormone receptors located on pituitary somatotroph cells.
Activation of these receptors stimulates growth hormone secretion, which subsequently influences insulin-like growth factor 1 (IGF-1) signaling and other endocrine processes.
Unlike AOD-9604, Tesamorelin has a well-established receptor mechanism and has undergone extensive clinical investigation.
Certain prescription formulations of Tesamorelin are FDA-approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.
However, those compounds are not approved for general weight-loss management.
The FDA approval applies to specific regulated pharmaceutical formulations and does not establish the clinical suitability of independently marketed research-grade Tesamorelin.
AOD-9604 vs Tesamorelin: Molecular Structure
Molecular structure plays a central role in determining how peptides behave in biological systems.
AOD-9604 and Tesamorelin differ in amino acid count, sequence origin, structural modifications, and molecular architecture.
AOD-9604 Molecular Structure
AOD-9604 contains 16 amino acid residues.
Its one-letter amino acid sequence is:
YLRIVQCRSVEGSCGF
The molecular formula is C₇₈H₁₂₃N₂₃O₂₃S₂, with an approximate molecular weight of 1,815.1 daltons.
The peptide contains an additional tyrosine residue at its N-terminus.
It also includes two cysteine residues that form an intramolecular disulfide bond.
This bond creates a constrained loop within the peptide chain.
These structural features are important when studying peptide conformation, chemical stability, and analytical identification.
Tesamorelin Molecular Structure
Tesamorelin contains 44 amino acid residues derived from human GHRH.
Its molecular weight is approximately 5,135.9 daltons.
The peptide contains an N-terminal trans-3-hexenoyl modification.
Unlike AOD-9604, Tesamorelin does not contain the same disulfide-bridged molecular structure.
Its sequence and modification allow it to interact with GHRH receptors.
This receptor-binding capability is central to its established biological activity.
Why Does Molecular Structure Matter?
Even small changes in a peptide’s amino acid sequence can influence receptor recognition, molecular conformation, chemical stability, and biological activity.
In the case of AOD-9604 and Tesamorelin, the differences are more substantial than a single amino acid substitution.
AOD-9604 originates from the growth hormone protein, whereas Tesamorelin is a modified analog of the hormone responsible for stimulating growth hormone secretion.
Consequently, their biological actions must be evaluated separately.
AOD-9604 vs Tesamorelin: Mechanism of Action
The most important scientific distinction between AOD-9604 and Tesamorelin is their mechanism of action.
Tesamorelin activates an established receptor pathway, while the primary molecular target of AOD-9604 remains incompletely characterized.
How Does AOD-9604 Work?
Early AOD-9604 studies focused on its potential influence on lipid metabolism.
Researchers examined whether the C-terminal growth hormone region could influence certain metabolic pathways without reproducing the complete hormone’s broader actions.
Three areas received particular attention.
1. Lipolysis
Lipolysis is the biological process through which stored triglycerides are broken down into fatty acids and glycerol.
Early animal studies investigated whether AOD-9604 influenced this process.
Some experiments reported changes in lipid metabolism under controlled conditions.
However, findings from animal experiments cannot independently establish equivalent outcomes in humans.
2. Lipogenesis
Lipogenesis describes processes involved in lipid synthesis and storage.
Researchers also examined the effects of AOD-9604 on pathways associated with fat accumulation.
Some preclinical results suggested changes in lipid-related activity.
These observations helped establish the compound’s original research direction.
Nevertheless, the findings did not lead to convincing clinical evidence of weight-loss effectiveness.
3. Beta-Adrenergic Signaling
Beta-adrenergic receptors participate in metabolic and cardiovascular signaling.
Some experiments investigated whether pathways involving these receptors contributed to the metabolic effects observed with AOD-9604.
A 2001 study published in Endocrinology examined the effects of AOD-9604 and human growth hormone in obese mice, including beta-3 adrenergic receptor knockout animals.
The study contributed to understanding potential experimental mechanisms, but it did not establish a definitive primary receptor for AOD-9604.
For a more detailed explanation, read Orion Peptides’ How AOD-9604 Works.
How Does Tesamorelin Work?
Tesamorelin acts through the growth hormone-releasing hormone receptor.
Its mechanism involves a sequence of endocrine signaling events.
GHRH receptor activation
Tesamorelin binds to GHRH receptors in the anterior pituitary gland.
Growth hormone secretion
Receptor activation stimulates the release of endogenous growth hormone.
IGF-1 production
Growth hormone promotes the production of insulin-like growth factor 1, particularly in the liver and other tissues.
Downstream biological signaling
Growth hormone and IGF-1 participate in metabolic regulation, tissue signaling, and other physiological activities.
Unlike AOD-9604, Tesamorelin’s receptor interactions and downstream endocrine effects have been demonstrated in pharmacological and clinical studies.
Do AOD-9604 and Tesamorelin Work Through the Same Pathway?
No.
AOD-9604 is a modified growth hormone fragment investigated for specific metabolic effects.
Tesamorelin is a GHRH receptor agonist that stimulates growth hormone secretion.
AOD-9604 should not be classified as a GHRH agonist, and there is no established evidence that it stimulates the same endocrine pathway as Tesamorelin.
AOD-9604 vs Tesamorelin in Metabolic Research
Although both peptides have been investigated in connection with metabolism, their clinical evidence differs considerably.
AOD-9604 Research Findings
Early laboratory and animal studies examined the potential effects of AOD-9604 on lipid metabolism.
Some preclinical findings encouraged the development of the compound as an experimental obesity-related drug.
AOD-9604 subsequently progressed into human clinical trials.
One of the most significant was the OPTIONS study conducted by Metabolic Pharmaceuticals.
The study enrolled 536 adults with obesity.
Investigators evaluated the effects of AOD-9604 compared with placebo.
The trial did not demonstrate a statistically significant weight-loss advantage for AOD-9604.
Following the unsuccessful clinical findings, the company’s obesity drug-development program was discontinued.
The FDA subsequently reviewed available AOD-9604 research and identified insufficient evidence supporting its effectiveness for obesity treatment.
Scientific reference: FDA AOD-9604 Scientific Review.
Tesamorelin Research Findings
Tesamorelin has been investigated in randomized clinical trials involving adults with HIV-associated lipodystrophy.
This condition can involve abnormal fat distribution, including excessive accumulation of visceral adipose tissue.
Visceral adipose tissue refers to fat located within the abdominal cavity around internal organs.
Clinical studies demonstrated reductions in visceral abdominal fat in the studied population.
These findings supported the approval of specific Tesamorelin prescription compounds.
However, this evidence is limited to defined clinical populations and outcomes.
Tesamorelin should not be described as an FDA-approved general weight-loss treatment.
According to the prescribing information for EGRIFTA WR, the compound is indicated for reducing excess abdominal fat in adults with HIV-associated lipodystrophy and is not indicated for weight-loss management.
Scientific reference: EGRIFTA WR Prescribing Information.
Comparing the Scientific Evidence
| Research consideration | AOD-9604 | Tesamorelin |
|---|---|---|
| Preclinical metabolic research | Yes | Yes |
| Human clinical trials | Yes | Yes |
| Established receptor mechanism | No | Yes |
| Demonstrated GH stimulation | No | Yes |
| Significant results in major obesity trial | Not demonstrated | Not approved for general obesity treatment |
| Clinical evidence for visceral fat reduction in HIV-associated lipodystrophy | Not established | Demonstrated |
| FDA-approved prescription indication | None | Specific indication |
The important distinction is the quality and relevance of clinical evidence.
Research findings must be interpreted according to the populations studied, the outcomes measured, and the design of the investigations.
Does AOD-9604 Increase Growth Hormone Like Tesamorelin?
There is no established evidence that AOD-9604 stimulates growth hormone secretion through the same mechanism as Tesamorelin.
Tesamorelin activates the GHRH receptor and stimulates endogenous growth hormone release.
AOD-9604 is derived from a fragment of the growth hormone molecule itself.
It was developed to investigate selected biological activities associated with that fragment rather than to reproduce the normal GHRH signaling pathway.
Therefore, the compounds should not be considered equivalent simply because both have a connection to growth hormone biology.
This distinction is particularly important in research involving peptide classification, receptor signaling, and endocrine mechanisms.
AOD-9604 vs Tesamorelin: Laboratory Research Differences
The different molecular structures of AOD-9604 and Tesamorelin create different analytical considerations.
For example, their molecular weights, amino acid sequences, and chemical modifications can influence how the compounds are identified and characterized in a laboratory.
Molecular Identification
AOD-9604 has an approximate molecular weight of 1,815.1 daltons.
Tesamorelin has an approximate molecular weight of 5,135.9 daltons.
This difference allows researchers to distinguish the expected molecular masses using suitable analytical techniques.
However, molecular mass alone does not establish the complete structure or purity of an individual sample.
High-Performance Liquid Chromatography
High-performance liquid chromatography, commonly called HPLC, is used to separate compounds in analytical samples.
The technique can help identify certain impurities and assess chromatographic purity.
Different peptides may exhibit different chromatographic retention characteristics because of their molecular properties.
Mass Spectrometry
Mass spectrometry measures mass-to-charge ratios and can provide information supporting compound identity.
For AOD-9604 and Tesamorelin, expected molecular masses can be compared with experimental measurements.
Additional methods may be required to confirm the amino acid sequence, chemical modifications, and other structural characteristics.
Peptide Stability
Stability is another important consideration in peptide research.
AOD-9604 contains a disulfide bridge, whereas Tesamorelin includes a different N-terminal modification.
These structural characteristics can influence their behavior under particular analytical and storage conditions.
Factors such as temperature, light, moisture, formulation, and chemical environment can also affect peptide degradation.
Appropriate stability conclusions require compound-specific experimental evidence rather than assumptions based on their classification as peptides.
AOD-9604 Research Materials at Orion Peptides
For laboratory studies involving AOD-9604, researchers may need information about molecular identity, labeled quantity, and analytical documentation.
Orion Peptides lists AOD-9604 in two research-material quantities:
Both listings refer to the same defined AOD-9604 molecular compound, with different nominal quantities.
Research material documentation should be considered separately from evidence of biological efficacy or suitability for clinical use.
For additional information about AOD-9604’s molecular properties, Orion Peptides also maintains an AOD-9604 technical learning resource.
These compounds are intended strictly for laboratory research and are not approved for human or veterinary administration.
Are AOD-9604 and Tesamorelin FDA-Approved?
Their regulatory status differs.
AOD-9604 FDA Status
AOD-9604 is not FDA-approved for any therapeutic indication.
Although it has been investigated in human clinical studies, available research has not established sufficient evidence of effectiveness for obesity treatment.
Tesamorelin FDA Status
Specific Tesamorelin prescription formulations are FDA-approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.
The approval does not extend to routine weight-loss management.
It also does not mean that research-grade Tesamorelin compounds sold independently are equivalent to approved pharmaceutical formulations.
These distinctions are important when evaluating research materials, clinical evidence, and regulatory claims.
Frequently Asked Questions About AOD-9604 vs Tesamorelin
What is the main difference between AOD-9604 and Tesamorelin?
AOD-9604 is a modified fragment of human growth hormone, while Tesamorelin is a synthetic growth hormone-releasing hormone analog. Tesamorelin stimulates growth hormone secretion through an established receptor pathway, whereas AOD-9604 has an incompletely characterized molecular mechanism.
Is AOD-9604 the same as Tesamorelin?
No. The compounds differ in amino acid sequence, molecular size, structure, receptor activity, and clinical evidence.
Does AOD-9604 stimulate growth hormone?
AOD-9604 has not been established as a growth hormone secretagogue. Unlike Tesamorelin, it does not have an established mechanism involving stimulation of pituitary GHRH receptors.
Is Tesamorelin a growth hormone fragment?
No. Tesamorelin is a synthetic analog of growth hormone-releasing hormone, not a fragment of the growth hormone protein.
How many amino acids are in AOD-9604 and Tesamorelin?
AOD-9604 contains 16 amino acid residues, while Tesamorelin contains 44.
Do AOD-9604 and Tesamorelin have the same mechanism of action?
No. Tesamorelin activates GHRH receptors to stimulate growth hormone secretion. AOD-9604 was investigated for metabolic effects associated with a modified growth hormone fragment.
Does AOD-9604 work for weight loss?
Human clinical trials did not establish a meaningful weight-loss benefit. A major study found no statistically significant improvement compared with placebo.
Is Tesamorelin approved for weight loss?
No. Certain Tesamorelin prescription compounds are FDA-approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, but they are not approved for general weight-loss management.
Is AOD-9604 FDA-approved?
No. AOD-9604 is not approved by the FDA for any therapeutic indication.
Can AOD-9604 and Tesamorelin be considered interchangeable?
No. Their different molecular structures, biological targets, and clinical evidence mean they should not be considered scientifically or therapeutically interchangeable.
Conclusion
The comparison of AOD-9604 vs Tesamorelin demonstrates how two synthetic peptides associated with growth hormone biology can have substantially different molecular structures, mechanisms, and research outcomes.
AOD-9604 is a modified 16-amino-acid fragment of human growth hormone. Its scientific history centers on lipid metabolism, peptide-fragment chemistry, and experimental metabolic signaling.
Tesamorelin is a 44-amino-acid GHRH analog that activates growth hormone-releasing hormone receptors and stimulates endogenous growth hormone secretion.
While both compounds have been investigated in metabolic research, their clinical evidence differs.
AOD-9604 did not demonstrate significant weight-loss efficacy in a major human trial, while Tesamorelin has evidence supporting its specific FDA-approved indication involving HIV-associated lipodystrophy.
For researchers, these differences highlight the importance of evaluating peptides according to their molecular structure, receptor activity, experimental findings, and clinical evidence rather than their broad association with growth hormone biology.
Research Use Disclaimer: This article is intended for scientific and educational purposes only. AOD-9604 is an investigational compound and is not FDA-approved. Research-grade peptides are not intended for human or veterinary consumption, diagnosis, treatment, or clinical use. The approval of specific Tesamorelin prescription compounds does not extend to independently marketed research materials.
Scientific References
- Heffernan MA et al. (2001). The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice and β3-AR Knock-Out Mice. Endocrinology. https://doi.org/10.1210/endo.142.12.8522
- U.S. Food and Drug Administration. (2024). AOD-9604-Related Bulk Drug Substances: Scientific Review. https://www.fda.gov/media/183584/download
- U.S. Food and Drug Administration. (2024). Pharmacy Compounding Advisory Committee: Clinical Evidence Review of AOD-9604. https://www.fda.gov/media/183891/download
- DailyMed. EGRIFTA WR (Tesamorelin) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75
